Mitragynine Pseudoindoxyl: Pharmacology, Risks & Safety Warning
Mitragynine pseudoindoxyl is a potent opioid-acting rearrangement product related to 7-hydroxymitragynine. Covers chemistry, pharmacology, absence of human safety data, and documented withdrawal risks.
Strong safety notice: This is educational harm-reduction content, not medical advice. Mitragynine pseudoindoxyl is a potent opioid-acting compound with no established safe dose and no FDA-approved use. Do not use products containing mitragynine pseudoindoxyl. Seek emergency care for slowed breathing, loss of consciousness, severe sedation, chest pain, blue lips, or inability to stay awake.
Evidence Snapshot
- Mitragynine pseudoindoxyl is a rearrangement product related to 7-hydroxymitragynine
- Shows high mu-opioid receptor activity in preclinical studies
- Some lab work describes G-protein-biased signaling — this does not prove human safety
- No controlled human clinical trials exist establishing safe use, therapeutic value, or pharmacokinetics
- Detected in unregulated products; tracked by forensic and public health groups
- Evidence grade for human effects: Very Low
What It Is
Mitragynine pseudoindoxyl is an opioid-active compound formed through rearrangement chemistry from 7-hydroxymitragynine. It can be produced synthetically and has been reported as a transformation product in human plasma under experimental conditions.
This table scrolls horizontally on small screens. Use Tab to focus the table region, then scroll with arrow keys or touch.
| Property | Summary |
|---|---|
| Chemical context | Rearrangement product related to 7-hydroxymitragynine |
| Molecular formula | C₂₃H₃₀N₂O₅ |
| Molecular weight | ~414.5 g/mol |
| Evidence base | In vitro pharmacology, preclinical studies, forensic reports, case reports |
| Human trials | None |
The compound has appeared in forensic and market surveillance reports, sometimes alongside 7-hydroxymitragynine, in products that blur the distinction between traditional kratom and concentrated opioid-active derivatives.
Pharmacology
Mitragynine pseudoindoxyl acts as a potent mu-opioid receptor agonist and delta-opioid receptor antagonist in preclinical studies. Some research emphasizes G-protein-biased signaling with limited beta-arrestin recruitment.
In vitro signaling bias does not translate to lower overdose, dependence, or respiratory risk in humans. The absence of controlled human safety data must dominate the conclusion.
This table scrolls horizontally on small screens. Use Tab to focus the table region, then scroll with arrow keys or touch.
| Evidence domain | What is known | Major limitation |
|---|---|---|
| Mu-opioid activity | High affinity in lab studies | Human exposure-response unknown |
| Delta-opioid activity | Delta antagonist described preclinically | Clinical significance not established |
| G-protein bias | Reported in some systems | Does not prove real-world safety |
| Human PK | No controlled trials | Onset, duration, accumulation, interactions all uncertain |
| Human adverse events | Withdrawal case reports exist [6, 7] | Cannot define safe or typical risk |
Clinical Evidence: None
There are no published controlled human trials showing mitragynine pseudoindoxyl is safe or effective for any medical use. Human evidence is limited to:
- Case reports: A 2026 report described severe early-onset withdrawal after intentional use [6]. Another 2026 report described withdrawal management in a regular user [7].
- Forensic monitoring: UNODC and CFSRE track its emergence in unregulated products [3, 4].
- Market surveillance: Products containing MP have been documented, sometimes mislabeled as "kratom" or "7-OH" [5].
Safety and Risks
Mitragynine pseudoindoxyl should be treated as a potent, poorly characterized opioid derivative. Documented and plausible risks include:
- Respiratory depression
- Profound sedation
- Physical dependence and withdrawal [6, 7]
- Accidental overdose
- Dangerous interactions with CNS depressants (alcohol, benzodiazepines, gabapentinoids, opioids)
Higher-risk populations: sleep apnea, chronic lung disease, liver disease, prior substance use disorder, concurrent sedating medications, or recent opioid tolerance changes.
Do not use mitragynine pseudoindoxyl. If exposure has occurred: do not combine with depressants, do not drive, do not use alone. Naloxone access is prudent, but emergency medical evaluation is essential for overdose symptoms.
Product and Labeling Concerns
Products containing mitragynine pseudoindoxyl may use terms like "kratom," "7-OH," "research," or branded names without clearly communicating the pharmacological difference from traditional leaf.
This table scrolls horizontally on small screens. Use Tab to focus the table region, then scroll with arrow keys or touch.
| Concern | Impact |
|---|---|
| Mislabeling | Consumers may unknowingly ingest a potent opioid derivative |
| Variable content | Tablets, liquids, powders may contain inconsistent amounts |
| Mixed derivatives | Products may combine 7-OH, MP, MGM-15, or other compounds |
| No clinical labeling | No standardized contraindications, interactions, or overdose guidance |
Key Takeaways
Mitragynine pseudoindoxyl is a potent opioid-active compound with no human safety data. Laboratory pharmacology (G-protein bias, receptor selectivity) does not guarantee safety. Withdrawal case reports exist. Unregulated products may obscure exposure risk. Avoid use. Treat any exposure as medically relevant when symptoms occur.
Related Content
References
- Varadi A, et al. Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism (2016) — Source
- Kamble SH, et al. Metabolism of a Kratom Alkaloid Metabolite in Human Plasma Increases Its Opioid Potency and Efficacy (2020) — Source
- Center for Forensic Science Research and Education Mitragynine Pseudoindoxyl (2025) — Source
- United Nations Office on Drugs and Crime Emergence of potent kratom-related products containing 7-hydroxymitragynine and/or mitragynine pseudoindoxyl (2025) — Source
- Hill R, Boyer EW, et al. De facto opioids: Characterization of novel 7-hydroxymitragynine and mitragynine pseudoindoxyl product marketing (2025) — Source
- Stanciu CN, et al. Severe Early-Onset Withdrawal Following Intentional Use of Mitragynine Pseudoindoxyl (2026) — Source
- Case report authors Mitragynine Pseudoindoxyl Withdrawal Treated with Macro-Dosed Buprenorphine (2026) — Source